Toxicity of small cell lung cancer treatment

Hematology/Oncology Clinics of North America

Volumn 18, Issue 2, 2004, Pages 461-481

  Casas, Francesc ^a   Viñolas, Núria ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FENTANYL; GRANULOCYTE COLONY STIMULATING FACTOR; MORPHINE; NORTRIPTYLINE; PENTOXIFYLLINE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; ROXITHROMYCIN; TRANSFORMING GROWTH FACTOR BETA; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE;

ANEMIA; ATROPHY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DYSPHAGIA; DYSPLASIA; ESOPHAGITIS; ESOPHAGUS INJURY; FEVER; FIBROSIS; HUMAN; INFECTION; KERATOSIS; LEUKOPENIA; LUNG SMALL CELL CANCER; LUNG TOXICITY; MORBIDITY; NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TOXICITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 1942471132     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2003.12.007     Document Type: Review

References (69)

1. Rubin P. Radiation toxicology: quantitative radiation pathology for predicting effects. Cancer. 39:1977;729-736.
2. Phillips T.L., Fu K.K. The interaction of drug and radiation effects on normal tissues. Int J Radiat Oncol Biol Phys. 4:1978;59-64.
3. Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L.et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 327:1992;1618-1624.
4. Murray N., Coy P., Pater J.L., Hodson I., Arnold A., Zee B.C.et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 11:1993;336-344.
5. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 15:1997;893-900.
6. Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.K., Komaki R.et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung treated concurrently with cisplatin and etoposide. N Engl J Med. 340:1999;265-271.
7. Takada M., Fukuoka M., Kawahara M., Sugiura T., Yokoyama A., Yokota S.et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group study 9104. J Cin Oncol. 20:2002;3054-3060.
8. Dewit L. Combined treatment of radiation and cis-diammine dischloro platinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 13:1987;403-426.
9. Pujol J.L., Carestia L., Daures J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 83:2000;8-15.
10. Mascaux C., Paesmans M., Berghmans T., Branle F., Lafitte J.J., Lemaitre F.et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 30:2000;23-36.
11. Videtic G.M., Fung K., Tomiak A.T., Stitt L.W., Dar A.R., Truong P.T.et al. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer. 33:2001;249-258.
12. Kovacs C.J., Evans M.J., Hooker J.L., Johnke R.M. Long-term consequences of chemotherapeutic agents on hematopoiesis: development of altered radiation tolerance. NCI Monogr. 6:1988;45-49.
13. Berghmans T., Paesmans M., Lafitte J.J., Mascaux C., Meert A.P., Sculier J.P. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer. 37:2002;115-123.
14. Adams J.R., Lyman G.H., Djubegovic B., Feinglass J., Bennet C.L. G-CSF as prophylaxis of febrile neutropenia in SCLC. Review of findings from 13 studies of cost-effectiveness, evidence-based guidelines, patterns of care and surveys of ASCO members. Expert Opin Pharmacother. 3:2002;1273-1281.
15. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A.et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 18:2000;3558-3585.
16. Tjan-Heijnen V.C., Postmus P.E., Ardizzoni A., Manegold C.H., Burghouts J., van Meerbeeck J.et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol. 12:2001;1359-1368.
17. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 322:1990;1689-1692.
18. Schapira L., Antin J.H., Ransil B.J., Antman K.H., Eder J.P., McGarigle C.J.et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood. 76:1990;2354-2359.
19. Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U.et al. Erythropoietin treatment in anemia associated with multiple myeloma. N Engl J Med. 322:1990;1693-1699.
20. de Campos E., Radford J., Steward W., Milroy R., Dougal M., Swindell R.et al. Clinical and in vitro effects of recombinant human erytropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol. 13:1995;1623-1631.
21. Zarogoulidis K., Papagiannis A., Ziogas E., Fahantidou E., Dermitzakis G., Gioulekas D.et al. Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur J Cancer. 33:1997;2428-2431.
22. Thatcher N., De Campos E.S., Bell D.R., Steward W.P., Varghese G., Morant R.et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 80:1999;396-402.
23. Henke M., Guttenberger R., Barke A., Pajonk F., Potter R., Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol. 50:1999;185-190.
24. Stuben G., Pottgen C., Knuhmann K., Schmidt K., Stuschke M., Thews O.et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys. 55:2003;1358-1362.
25. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 91:2000;2214-2221.
26. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D.et al. Use of epoetin in patients with cancer: evidence- based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 20:2002;4083-4107.
27. Casas F., Viñolas N., Ferrer F., Farrús B., Gimferrer J.M., Agustí C.et al. Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 55:2003;116-124.
28. MacRae R., Shyr Y., Johnson D., Choy H. Declining hemoglobin during chemoradio-therapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol. 64:2002;37-40.
29. Robnett T.J., Machtay M., Hahn S.M., Shrager J.B., Friedberg J.S., Kaiser L.R. Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients. Cancer J. 8:2002;263-267.
30. Yuen A.R., Zou G., Turrisi A.T., Sause W., Komaki R., Wagner H.et al. Similar outcome of elderly patients in Intergroup Trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 89:2000;1953-1960.
31. Baraldi-Junkins C.A., Beck A.C., Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin N Am. 14:2000;45-61.
32. Balducci L., Hardy C.L. Anemia of aging: a model of erythropoiesis in cancer patients. Cancer Control. 5:1998;17-21.
33. Balducci L., Hardy C.L., Lyman G.H. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control. 7:2000;539-547.
34. Vadhan-Raj S. Recombinant human thrombopoietin in myelosuppressive chemotherapy. Oncology. 15:2001;35-38.
35. Johnson P.W., Muers M.F., Peake M.D., Poulter K.M., Gurney E.M., Napp V.V.et al. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. Br J Cancer. 84:2001;19-24.
36. Schmidinger M., Budinsky A.C., Wenzel C., Piribauer M., Brix R., Kautzky M.et al. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr. 112:2000;617-623.
37. Mascarenhas F., Silvestre M.E., Sa da Costa M., Grima N., Campos C., Chaves P. Acute secondary effects in the esophagus in patients undergoing radiotherapy for carcinoma of the lung. Am J Clin Oncol. 12:1989;34-40.
38. Jatoi A., Thomas C.R. Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. Semin Radiat Oncol. 12:2002;62-67.
39. Choy H., LaPorte K., Knill-Selby E., Mohr P., Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol. 9:1999;90-96.
40. Werner-Wasik M., Pequignot E., Leeper D., Hauck W., Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys. 48:2000;689-696.
41. Maguire P.D., Sibley G.S., Zhou S.M., Jamieson T.A., Light K.L., Antonie P.A.et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 45:1999;97-103.
42. Choi N.C., Herndon J.E., Rosenman J., Carey R.W., Chung C.T., Bernard S.et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 16:1998;3528-3536.
43. Choi N.C., Carey R.W., Daly W., Mathisen D., Wain J., Wright C.et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 15:1997;712-722.
44. Arquette M., Wasserman T., Govindan R., Garfield D., Senzer N., Gillenwater H.et al. Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. Semin Radiat Oncol. 12:2002;59-61.
45. Antonadou D. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Semin Radiat Oncol. 12:2002;50-58.
46. Komaki R., Lee J.S., Kaplan B., Allen P., Kelly J.K., Liao Z.et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non small cell lung cancer: preliminary results. Semin Radiat Oncol. 12:2002;46-49.
47. Marks L.B., Munley M.T., Bentel G.C., Zhou S.M., Hollis D., Scarfone C.et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 39:1997;563-570.
48. Theuws J.C., Muller S.H., Seppenwoolde Y., Kwa S.L., Boersma L.J., Hart G.A.et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: a follow-up study. J Clin Oncol. 17:1999;3091-3100.
49. Thames H.D., Withers H.R., Peters L.J., Fletcher G.H. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys. 8:1982;219-226.
50. Yamada M., Kudoh S., Hirata K., Nakajima T., Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 34:1998;71-75.
51. Khan M.A., Hill R.P., Van Dyk J. Partial volume rat lung irradiation: an evaluation of early DNA damage. Int J Radiat Oncol Biol Phys. 40:1998;467-476.
52. Gopal R., Starkschall G., Tucker S.L., Cox J.D., Liao Z., Hanus M.et al. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 56:2003;114-120.
53. Seppenwoolde Y., Lebesque J.V., De Jaeger K., Belderbos J.S., Boersma L.J., Schilstra C.et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys. 55:2003;724-735.
54. Tsujino K., Hirota S., Endo M., Obayashi K., Kotani Y., Satouchi M.et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 55:2003;110-115.
55. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A.et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:1999;323-329.
56. Jenkins P., D'amico K., Benstead K., Elyan S. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys. 56:2003;360-366.
57. Hernando M.L., Marks L.B., Bentel G.C., Zhou S.M., Hollis D., Das S.K.et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;650-659.
58. Dileto C.L., Travis E.L. Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: comparison between a fibrosis-prone and fibrosis-resistant mouse strain. Radiat Res. 146:1996;61-67.
59. Geara F.B., Komaki R., Tucker S.L., Travis E.L., Cox J.D. Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. Int J Radiat Oncol Biol Phys. 41:1998;279-286.
60. Anscher M., Murase T., Prescott D.M., Marks L.B., Reisenbichler H., Bentel G.C.et al. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys. 30:1994;671-676.
61. Fu X.L., Huang H., Bentel G., Clough R., Jirtle R.L., Kong F.M.et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V (30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys. 50:2001;899-908.
62. Anscher M.S., Marks L.B., Shafman T.D., Clough R., Huang H., Tisch A.et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol. 19:2001;3758-3765.
63. Rübe C.E., Wilfert F., Uthe D., Schmid K.W., Knoop R., Willich N.et al. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol. 64:2002;177-187.
64. Delanian S., Balla-Mekias S., Lefaix J.L. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol. 17:1999;3283-3290.
65. Martel M.K., Sahijdak W.M., Ten Haken R.K., Kessler M.L., Turrisi A.T. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys. 40:1998;155-161.
66. Sandri M.T., Cardinale D., Zorzino L., Passerini R., Lentati P., Martinoni A.et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 49:2003;248-252.
67. Hammack J.E., Michalak J.C., Loprinzi C.L., Sloan J.A., Novotny P.J., Soori G.S.et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 98:2002;195-203.
68. Pace A., Savarese A., Picardo M., Maresca V., Paccetti U., Del Monte G.et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 21:2003;927-931.
69. Jeremic B., Shibamoto Y., Nikolic N., Milicic B., Milisavljevic S., Dagovic A.et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 17:1999;2092-2099.